Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 11/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.35 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.34 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16255784 | 1.00 | P2RY2 (0.40) | P2RY2P2RY6P2RY14P2RY4SLC28A1 | |
| SCHEMBL19112430 | 1.00 | P2RY2 (0.40) | P2RY2P2RY6P2RY14P2RY4SLC28A1 | |
| SCHEMBL18687612 | 0.89 | P2RY6 (0.36) | P2RY2P2RY6P2RY14P2RY4SLC28A1 | |
| SCHEMBL15375889 | 0.86 | P2RY2 (0.35) | P2RY2P2RY6P2RY14P2RY4 | |
| SCHEMBL17972480 | 0.83 | POLB (0.36) | P2RY2P2RY6P2RY14P2RY4 | |
| SCHEMBL14102275 | 0.83 | POLB (0.36) | P2RY2P2RY6P2RY14P2RY4 | |
| SCHEMBL21418943 | 0.83 | POLB (0.36) | P2RY2P2RY6P2RY14P2RY4 | |
| SCHEMBL16576220 | 0.83 | POLB (0.36) | P2RY2P2RY6P2RY14P2RY4 | |
| SCHEMBL21345265 | 0.81 | P2RY6 (0.42) | P2RY2P2RY6P2RY14P2RY4SLC28A1 | |
| SCHEMBL16305898 | 0.80 | POLB (0.40) | P2RY2P2RY6P2RY14P2RY4SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140369959-A1 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140369959-A1 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RNGTT, NSUN2, NSUN3 | P2RY2 961/4885P2RY6 759/4885P2RY14 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.